We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Indications -- Cancer
An SI Board Since March 2001
Posts SubjectMarks Bans
1840 101 0
Emcee:  Spekulatius Type:  Unmoderated
indication-specific file folder for cancer drugs / treatments
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1840BMY's LAG-3 data in melanoma: investorshub.advfn.comDewDiligence_on_SI1May 19
1839ATRA, Bayer ink_drug-development_collaboration_for_allogeneic_CAR-T_in_solid_tumDewDiligence_on_SI-12/7/2020
1838The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic natunigel bates-7/29/2020
1837Experimental approach to cancer treatment borrows a tenet from insect refuges: iDewDiligence_on_SI11/7/2020
1836Cancers (Basel). 2019 Nov 27;11(12). pii: E1883. doi: 10.3390/cancers11121883. scaram(o)uche-12/9/2019
1835Thanks, Miljenko. I didn't have time to explore much. The article suggeststuck-12/5/2019
1834Vanderbilt is who hold two PA on WDR5 inhibitors.Miljenko Zuanic-12/5/2019
1833Interaction of the oncoprotein transcription factor MYC with its chromatin cofactuck112/5/2019
1832Eur J Immunol. 2019 Nov;49(11):2083-2094. doi: 10.1002/eji.201848039. Epub 2019 scaram(o)uche-11/20/2019
1831Elife. 2019 Nov 19;8. pii: e50223. doi: 10.7554/eLife.50223. [Epub ahead of prinscaram(o)uche-11/20/2019
1830(not so much because I'm interested, more just from following up on todayscaram(o)uche-10/29/2019
1829I/O? Is that still a thing? ;-(scaram(o)uche-10/29/2019
1828PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrnigel bates110/24/2019
1827Cancer Immunol Res. 2019 Aug 26. pii: canimm.0008.2019. doi: 10.1158/2326-6066.Cscaram(o)uche-8/28/2019
1826Cancer Cell. 2019 Feb 11;35(2):221-237.e8. doi: 10.1016/j.ccell.2019.01.002. Anscaram(o)uche-2/13/2019
1825Blood. 2019 Jan 17. pii: blood-2018-07-864538. doi: 10.1182/blood-2018-07-864538scaram(o)uche-1/19/2019
1824B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependentscaram(o)uche-12/23/2018
1823Oncoimmunology. 2018 Sep 5;8(1):e1512943. doi: 10.1080/2162402X.2018.1512943. eCscaram(o)uche-12/14/2018
1822NTGN IPOs @$16; EV ~$350M: investorshub.advfn.comDewDiligence_on_SI-6/26/2018
1821Many people in that boat.DewDiligence_on_SI-3/8/2018
1820RE: NKTR What a stupid idiot I was on NKTR! :-(Miljenko Zuanic-3/8/2018
1819Thanks. So, the best way is to develop drug for ultra-orphan indication, and prMiljenko Zuanic-3/6/2018
1818The high initial price of Opdivo in Japan was for 2mg/kg dosing in melanoma: epDewDiligence_on_SI-3/6/2018 <After the newest cut, Opdivo will cost ¥278,000 per 1Miljenko Zuanic-3/6/2018
1816MRK show no sign it may slow down. Contrary,... fiercepharma.comMiljenko Zuanic-2/14/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):